Correction to: FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation (Nature Communications, (2019), 10, 1, (448), 10.1038/s41467-018-08271-x);FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation

Nature Communications

Volumn 10, Issue 1, 2019, Pages

  Yan, Jun ^a,b,c   Zhao, Qingnan ^c   Gabrusiewicz, Konrad ^a   Kong, Ling Yuan ^a   Xia, Xueqing ^c   Wang, Jian ^a   Ott, Martina ^a   Xu, Jingda ^a   Davis, R Eric ^a   Huo, Longfei ^c   Rao, Ganesh ^a   Sun, Shao Cong ^a   Watowich, Stephanie S ^a   Heimberger, Amy B ^a   Li, Shulin ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD103 ANTIGEN; FIBRINOGEN; FIBRINOGEN LIKE PROTEIN 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 2; STAT1 PROTEIN; STAT5 PROTEIN; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; ALPHA E INTEGRINS; ALPHA INTEGRIN; FGL2 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE P38; STAT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; FLOW CYTOMETRY; GLIOBLASTOMA; GLIOMA STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; BRAIN TUMOR; CANCER STEM CELL; CD4+ T LYMPHOCYTE; DISEASE EXACERBATION; GENE EXPRESSION REGULATION; GENETICS; GLIA; IMMUNOLOGY; MORTALITY; PATHOLOGY; SURVIVAL ANALYSIS; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTIGENS, CD; BRAIN NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; DENDRITIC CELLS; DISEASE PROGRESSION; FIBRINOGEN; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HETEROGRAFTS; HUMANS; INTEGRIN ALPHA CHAINS; MICE; MICE, TRANSGENIC; NEOPLASTIC STEM CELLS; NEUROGLIA; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; STAT TRANSCRIPTION FACTORS; SURVIVAL ANALYSIS; TUMOR BURDEN;

EID: 85060541473     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-019-08770-5     Document Type: Erratum

References (73)

1. Prasetyanti, P. R. & Medema, J. P. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol. Cancer 16, 41 (2017).
2. Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396–401 (2004).
3. Wainwright, D. A. et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin. Cancer Res. 18, 6110–6121 (2012).
4. Gardner, A. & Ruffell, B. Dendritic cells and cancer immunity. Trends Immunol. 37, 855–865 (2016).
5. Roberts, E. W. et al. Critical role for CD103 + /CD141 + dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. 30, 324–336 (2016).
6. Marazzi, S. et al. Characterization of human fibroleukin, a fibrinogen-like protein secreted by T lymphocytes. J. Immunol. 161, 138–147 (1998).
7. McGilvray, I. D. et al. Murine hepatitis virus strain 3 induces the macrophage prothrombinase fgl-2 through p38 mitogen-activated protein kinase activation. J. Biol. Chem. 273, 32222–32229 (1999).
8. Yan, J. et al. FGL2 as a multimodality regulator of tumor-mediated immune suppression and therapeutic target in gliomas. J. Natl Cancer Inst. 107, djv137 (2015).
9. Chan, C. W. Y. et al. Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells. J. Immunol. 170, 4036–4044 (2003).
10. Rabizadeh, E. et al. The cell-membrane prothrombinase, fibrinogen-like protein 2, promotes angiogenesis and tumor development. Thromb. Res. 136, 118–124 (2015).
11. Fidler, I. J., Balasubramanian, K., Lin, Q., Kim, S. W. & Kim, S. J. The brain microenvironment and cancer metastasis. Mol. Cells 30, 93–98 (2010).
12. Preusser, M. et al. Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. ESMO Open 3, e000262 (2018).
13. Chen, D. S. & Mellman, I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity. 39, 1–10 (2013).
14. Shalev, I. et al. The role of FGL2 in the pathogenesis and treatment of hepatitis C virus infection. Rambam Maimonides Med. J. 1, e0004 (2010).
15. Kaech, S. M. & Ahmed, R. Memory CD8 + T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat. Immunol. 2, 415–422 (2001).
16. Hildner, K. et al. Batf3 deficiency reveals a critical role for CD8a + dendritic cells in cytotoxic T cell immunity. Science 322, 1097–1100 (2008).
17. Ferris, S. T. et al. A minor subset of Batf3-dependent antigen-presenting cells in islets of langerhans is essential for the development of autoimmune diabetes. Immunity 41, 657–669 (2014).
18. Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 31, 711–723.e4 (2017).
19. Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 26, 638–652 (2014).
20. Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523, 231–235 (2015).
21. Lazarevic, V., Glimcher, L. H. & Lord, G. M. T-bet: A bridge between innate and adaptive immunity. Nat. Rev. Immunol. 13, 777–789 (2013).
22. Salmon, H. et al. Expansion and activation of CD103 + dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44, 924–938 (2016).
23. Mempel, T. R., Henrickson, S. E. & Von Andrian, U. H. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427, 154–159 (2004).
24. Liang, F. et al. Vaccine priming is restricted to draining lymph nodes & controlled by adjuvant-mediated antigen uptake. Sci. Transl. Med. 9, eaal2094 (2017).
25. Idzko, M. et al. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J. Clin. Invest. 116, 2935–2944 (2006).
26. Zhang, J.-G. et al. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity 36, 646–657 (2012).
27. Poulin, L. F. et al. DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues. Blood 119, 6052–6062 (2012).
28. Mayer, C. T. et al. Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow. Blood 124, 3081–3092 (2014).
29. Belz, G. T. & Nutt, S. L. Transcriptional programming of the dendritic cell network. Nat. Rev. Immunol. 12, 101–113 (2012).
30. Van De Laar, L., Coffer, P. J. & Woltman, A. M. Regulation of dendritic cell development by GM-CSF: Molecular control and implications for immune homeostasis and therapy. Blood 119, 3383–3393 (2012).
31. Perng, P. & Lim, M. Immunosuppressive mechanisms of malignant gliomas: parallels at non-CNS sites. Front. Oncol. 5, 153 (2015).
32. Hussain, S. F. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro. Oncol. 8, 261–279 (2006).
33. Gabrusiewicz, K. et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight 1, e85841 (2016).
34. Raychaudhuri, B. et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro. Oncol. 13, 591–599 (2011).
35. Matyszak, M. K. et al. Microglia induce myelin basic protein-specific T cell anergy or T cell activation, according to their state of activation. Eur. J. Immunol. 29, 3063–3076 (1999).
36. Quail, D. F. & Joyce, J. A. The microenvironmental landscape of brain tumors. Cancer Cell. 31, 326–341 (2017).
37. Zhai, H., Heppner, F. L. & Tsirka, S. E. Microglia/macrophages promote glioma progression. Glia 59, 472–485 (2011).
38. Candolfi, M. et al. Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics. Neoplasia 14, 757–IN26 (2012).
39. Le Bon, A. et al. Cross-priming of CD8 + T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4, 1009–1015 (2003).
40. Tamoutounour, S. et al. Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. Immunity 39, 925–938 (2013).
41. Ricard, C. et al. Phenotypic dynamics of microglial and monocyte-derived cells in glioblastoma-bearing mice. Sci. Rep. 6, 26381 (2016).
42. Sánchez-Paulete, A. R. et al. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Ann. Oncol. 28, xii44–xii55 (2017).
43. Haniffa, M. et al. Human tissues contain CD141 hi cross-presenting dendritic cells with functional homology to mouse CD103 + nonlymphoid dendritic cells. Immunity 37, 60–73 (2012).
44. Quintana, E. et al. DNGR-1 + dendritic cells are located in meningeal membrane and choroid plexus of the noninjured brain. Glia 63, 2231–2248 (2015).
45. Lau-Kilby, A. W. et al. Interleukin-2 inhibits FMS-like tyrosine kinase 3 receptor ligand (flt3L)-dependent development and function of conventional and plasmacytoid dendritic cells. Proc. Natl Acad. Sci. USA 108, 2408–2413 (2011).
46. Zhan, Y., Xu, Y. & Lew, A. M. The regulation of the development and function of dendritic cell subsets by GM-CSF: More than a hematopoietic growth factor. Mol. Immunol. 52, 30–37 (2012).
47. Helft, J. et al. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c + MHCII + macrophages and dendritic cells. Immunity 42, 1197–1211 (2015).
48. Greter, M. et al. GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity 36, 1031–1046 (2012).
49. Yan, W.-L., Shen, K.-Y., Tien, C.-Y., Chen, Y.-A. & Liu, S.-J. Recent progress in GM-CSF-based cancer immunotherapy. Immunotherapy 9, 347–360 (2017).
50. Parmiani, G. et al. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol. 18, 226–232 (2007).
51. Hong, I. S. Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types. Exp. Mol. Med. 48, e242 (2016).
52. Creelan, B. C. et al. Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J. Immunother. 36, 442–450 (2013).
53. Faries, M. B., Hsueh, E. C., Ye, X., Hoban, M. & Morton, D. L. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin. Cancer Res. 15, 7029–7035 (2009).
54. Westermann, J., Hecker, A. C., Flörcken, A., Dörken, B. & Pezzutto, A. Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus??-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: Induction of CD80/86+T cells indicates adverse outcome. J. Immunother. 32, 667–675 (2009).
55. Revoltella, R. P., Menicagli, M. & Campani, D. Granulocyte-macrophage colony-stimulating factor as an autocrine survival-growth factor in human gliomas. Cytokine 57, 347–359 (2012).
56. Choi, J. K., Kim, K. H., Park, H., Park, S. R. & Choi, B. H. Granulocyte macrophage-colony stimulating factor shows anti-apoptotic activity in neural progenitor cells via JAK/STAT5-Bcl-2 pathway. Apoptosis 16, 127–134 (2011).
57. Li, H. S. et al. The signal transducers STAT5 and STAT3 control expression of Id2 and E2-2 during dendritic cell development. Blood 120, 4363–4373 (2012).
58. Louis, D. N. et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97–109 (2007).
59. Shalev, I. et al. Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis. J. Immunol. 180, 249–260 (2008).
60. Latha, K. et al. The role of fibrinogen-like protein 2 on immunosuppression and malignant progression in glioma. J. Natl Cancer Inst. djy107 (2018).
61. Wei, J. et al. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res. 73, 3913–3926 (2013).
62. Jost, S. C., Collins, L., Travers, S., Piwnica-Worms, D. & Garbow, J. R. Measuring brain tumor growth: combined bioluminescence imaging-magnetic resonance imaging strategy. Mol. Imaging. 8, 245–253 (2009)
63. Sokolovska, A. et al. Activation of caspase-1 by the NLRP3 inflammasome regulates the NADPH oxidase NOX2 to control phagosome function. Nat. Immunol. 14, 543–553 (2013).
64. Blaskovich, M. A. et al. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 63, 1270–1279 (2003).
65. Senger, K. et al. The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation. Sci. Signal. 10, eaah4273 (2017).
66. Sathe, P. et al. The acquisition of antigen cross-presentation function by newly formed dendritic cells. J. Immunol. 186, 5184–5192 (2011).
67. Jin, D. et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 70, 2245–2255 (2010).
68. Mitchell, T. C. et al. Immunological adjuvants promote activated T cell survival via induction of Bcl-3. Nat. Immunol. 2, 397–402 (2001).
69. Koenen, P. et al. Mutually exclusive regulation of T cell survival by IL-7R and antigen receptor-induced signals. Nat. Commun. 4, 1735 (2013).
70. Caruana, I. et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat. Med. 21, 524–529 (2015).
71. LaFrance-Corey, R. G. & Howe, C. L. Isolation of brain-infiltrating leukocytes. J. Vis. Exp. 10.3791/2747 (2011).
72. Verhaak, R. G. W. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17, 98–110 (2010).
73. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).